Top-News

Teva Pharmaceutical Aktie (ADR) News

Aktie
WKN:  883035 ISIN:  US8816242098 US-Symbol:  TEVA Branche:  Pharmazeutika Land:  Israel
24,50 €
+0,1 €
+0,41%
14:47:10 Uhr
Depot/Watchlist
Marktkapitalisierung *
25,14 Mrd. €
Streubesitz
39,66%
KGV
-15,52
Dividende
0,071 €
Dividendenrendite
0,29%
Faktor
1
Originalaktie
IL0006290147
Weiter aufwärts? Long handeln - Jetzt mit Hebel 8,11: VH0A9A
Werbung

Teva Pharmaceutical Aktie (ADR) News

22.02.25 - GlobeNewswire
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET
21.02.25 - GlobeNewswire
Der Patient steht an erster Stelle: Warum Europa handeln muss, um den Zugang zu Arzneimitteln zu sichern
AMSTERDAM, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Laut einer neuen Studie von Teva Pharmaceuticals Europe werden 46 % der Generika auf der EU-Liste der kritischen ...
21.02.25 - GlobeNewswire
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, t he U. S. Food and Drug Administration (FDA) approved SELARSDI ™ for all indications matching the reference product Stelara ® ( ustekinumab ) and has ...
18.02.25 - GlobeNewswire
Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)
TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will conduct a conference call and live ...
18.02.25 - GlobeNewswire
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and ...
17.02.25 - Boersia.de
Teva Pharmaceutical Aktie: Ernsthafte Fragezeichen?
Der israelische Pharmakonzern Teva Pharmaceutical Industries verzeichnet aktuell eine rückläufige Entwicklung an der Börse. Der Aktienkurs liegt derzeit bei 15,45 EUR und weist ...
29.01.25 - GlobeNewswire
Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth
2024 Revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023; AUSTEDO ® - exceeding $1.6 billion in revenues, surpassing 2024 outlook; ...
27.01.25 - GlobeNewswire
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and ...
14.01.25 - GlobeNewswire
Teva gibt Zusammenarbeit zur Vermarktung des Formycon Biosimilar-Kandidaten für Eylea® (Aflibercept) in großen Teilen Europas und in Israel bekannt
Klinge Biopharma GmbH (Klinge) besitzt die exklusiven weltweiten Vermarktungsrechte für FYB203, Formycons Biosimilar-​Kandidat für Eylea ®1 Die Vereinbarung basiert auf der ...
13.01.25 - GlobeNewswire
Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel
Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea ® 1 Agreement builds on the proven and ...
10.01.25 - GlobeNewswire
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
Marks a step forward in b roadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH) , atypical hemolytic uremic syndrome ( aHUS ) and generalized ...
23.12.24 - GlobeNewswire
Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference
TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and ...
20.12.24 - GlobeNewswire
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025
TEL AVIV, Israel, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth ...
17.12.24 - dpa-AFX
AKTIEN IM FOKUS: Studiendaten zünden Teva-Kurs­feuerwerk - Auch Sanofi beflügelt
Aus der Pharmabranche haben am Dienstag die Aktien von Teva an der New Yorker Börse mit einem Kurssprung um mehr als ein Viertel Schlagzeilen gemacht. Den Anstoß dazu, ...
17.12.24 - GlobeNewswire
Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
Teva hosting investor call today at 8:00 a.m. ET (U.S.)
11.12.24 - GlobeNewswire
Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients
Teva to provide two generic inhaler products to Direct Relief for its network of free and charitable clinics The program , launc hing this month, will run for a minimum of three years ...
06.12.24 - GlobeNewswire
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
Teva entered into an agreement with JKI Co., Ltd. ( “JKI” ) established by the fund managed and operated by private equity firm J-Will Partners Co., Ltd. ("J-Will”), through which JKI will ...

Newssuche

Videos

newspaper
10:20 Uhr +1,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »